![]() ![]() Novavax (NVAX-2.90) soared a jaw-dropping 7,900 from the start of 2020 through its peak last February. The Company has developed and begun commercialization of its. Novavax is the seventh company with which the EU has signed a supply deal for COVID-19 vaccines. The company was one of investors early favorites in the vaccine race. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The bloc also has supply deals with AstraZeneca (AZN.L) and Johnson & Johnson (JNJ.N) which both produce viral vector vaccines against COVID-19, but the EU has reduced its reliance on these shots after health concerns and supply problems. ![]() It has also booked 405 million doses of the mRNA vaccine developed by CureVac (5CV.DE), although the vaccine has so far shown limited efficacy in tests and has not yet been approved by regulators. The company which has its COVID-19 vaccine as the only marketed product after 35 years in business on Tuesday flagged significant uncertainty around its 2023 revenue, funding from the U.S. Although the company reported in June that its vaccine had an efficacy of 90 percent against symptomatic Covid-19 cases, and 100 percent against severe disease, Novavax has struggled for months to. The EU has reserved a total of 2.4 billion doses of the Pfizer-BioNTech vaccine in three different contracts, and has also bought 460 million Moderna shots, clear signs of its preference for mRNA jabs. ![]() "As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population," European Commission President Ursula von der Leyen said. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |